KNApSAcK Metabolite C00018065
Metabolite
KNApSAcK Entry
| id | C00018065 |
|---|---|
| Name | Aclacur / Jaclacin / NSC 208734 / Aclarubicin / Aclacinomycin A / Antibiotic 3082A / Antibiotic MA 144A1 / Antibiotic 77-3082A |
| CAS RN | 57576-44-0 |
| Standard InChI | InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1 |
| Standard InChI (Main Layer) | InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3 |
Cluster
| Phytochemical cluster | |
|---|---|
| KCF-S cluster | No. 175 |
Link
ChEMBL
| By standard InChI | CHEMBL502620 |
|---|---|
| By standard InChI Main Layer | CHEMBL45414 CHEMBL502620 CHEMBL2009694 |
KEGG
| By LinkDB | C18638 |
|---|
CTD
| By CAS RN | D015250 |
|---|
Species
Summary
Plant class
| class name | count |
|---|
Family
| family name | count |
|---|---|
| Streptomycetaceae | 1 |
List (1)
* NCBI
| KNApSAcK organism | *ID | *family | *plant class | *kingdom |
|---|---|---|---|---|
| Streptomyces galilaeus No. MA144-M1 (ATCC 31133) | 1883 | Streptomycetaceae | Bacteria |
Human Protein / Gene in interaction
91 ChEMBL Protein in interactions
| accession | description | class description | compound | assay ID (# of activities) |
# of diseases
(OMIM / KEGG) |
|---|---|---|---|---|---|
| P10635 | Cytochrome P450 2D6 | Cytochrome P450 2D6 | CHEMBL502620 |
CHEMBL1909136
(2)
|
1 / 0 |
| P21728 | D(1A) dopamine receptor | Dopamine receptor | CHEMBL502620 |
CHEMBL1909139
(2)
|
0 / 0 |
| P35354 | Prostaglandin G/H synthase 2 | Oxidoreductase | CHEMBL502620 |
CHEMBL1909131
(2)
|
0 / 3 |
| Q12809 | Potassium voltage-gated channel subfamily H member 2 | KCNH, Kv10-12.x (Ether-a-go-go) | CHEMBL502620 |
CHEMBL1909190
(2)
|
2 / 2 |
| P08246 | Neutrophil elastase | S1A | CHEMBL502620 |
CHEMBL1909195
(2)
|
2 / 1 |
| P33765 | Adenosine receptor A3 | Adenosine receptor | CHEMBL502620 |
CHEMBL1909215
(2)
|
0 / 0 |
| Q16539 | Mitogen-activated protein kinase 14 | p38 | CHEMBL502620 |
CHEMBL1909201
(2)
|
0 / 0 |
| P49146 | Neuropeptide Y receptor type 2 | Neuropeptide Y receptor | CHEMBL502620 |
CHEMBL1909176
(2)
|
0 / 0 |
| P29466 | Caspase-1 | C14 | CHEMBL502620 |
CHEMBL1909193
(2)
|
0 / 0 |
| P17252 | Protein kinase C alpha type | Alpha | CHEMBL502620 |
CHEMBL1909198
(2)
|
0 / 0 |
| P27361 | Mitogen-activated protein kinase 3 | Erk | CHEMBL502620 |
CHEMBL1909199
(2)
|
0 / 0 |
| P14780 | Matrix metalloproteinase-9 | M10A | CHEMBL502620 |
CHEMBL1909197
(2)
|
2 / 2 |
| P00918 | Carbonic anhydrase 2 | Lyase | CHEMBL502620 |
CHEMBL1909123
(2)
|
1 / 2 |
| P07550 | Beta-2 adrenergic receptor | Adrenergic receptor | CHEMBL502620 |
CHEMBL1909092
(2)
|
0 / 1 |
| P21397 | Amine oxidase [flavin-containing] A | Oxidoreductase | CHEMBL502620 |
CHEMBL1909169
(2)
|
1 / 1 |
| P25021 | Histamine H2 receptor | Histamine receptor | CHEMBL502620 |
CHEMBL1909157
(2)
|
0 / 0 |
| P35367 | Histamine H1 receptor | Histamine receptor | CHEMBL502620 |
CHEMBL1909156
(2)
|
0 / 0 |
| Q01959 | Sodium-dependent dopamine transporter | Dopamine | CHEMBL502620 |
CHEMBL1909143
(2)
|
1 / 0 |
| P08912 | Muscarinic acetylcholine receptor M5 | Acetylcholine receptor | CHEMBL502620 |
CHEMBL1909174
(2)
|
0 / 0 |
| P18825 | Alpha-2C adrenergic receptor | Adrenergic receptor | CHEMBL502620 |
CHEMBL1909090
(2)
|
0 / 0 |
| P13945 | Beta-3 adrenergic receptor | Adrenergic receptor | CHEMBL502620 |
CHEMBL1909093
(2)
|
0 / 0 |
| P25024 | C-X-C chemokine receptor type 1 | CXC chemokine receptor | CHEMBL502620 |
CHEMBL1909127
(2)
|
0 / 0 |
| P06241 | Tyrosine-protein kinase Fyn | Src | CHEMBL502620 |
CHEMBL1909204
(2)
|
0 / 0 |
| Q08209 | Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform | Ser_Thr | CHEMBL502620 |
CHEMBL1909202
(2)
|
0 / 0 |
| P11712 | Cytochrome P450 2C9 | Cytochrome P450 2C9 | CHEMBL502620 |
CHEMBL1909135
(2)
|
0 / 1 |
| P00533 | Epidermal growth factor receptor | TK tyrosine-protein kinase EGFR subfamily | CHEMBL502620 |
CHEMBL1909203
(2)
|
1 / 11 |
| P14416 | D(2) dopamine receptor | Dopamine receptor | CHEMBL502620 |
CHEMBL1909140
(2)
|
2 / 0 |
| P23219 | Prostaglandin G/H synthase 1 | Oxidoreductase | CHEMBL502620 |
CHEMBL1909130
(2)
|
0 / 0 |
| P37288 | Vasopressin V1a receptor | Vasopressin and oxytocin receptor | CHEMBL502620 |
CHEMBL1909120
(2)
|
0 / 0 |
| P41145 | Kappa-type opioid receptor | Opioid receptor | CHEMBL502620 |
CHEMBL1909181
(2)
|
0 / 0 |
| Q9Y271 | Cysteinyl leukotriene receptor 1 | Leukotriene receptor | CHEMBL502620 |
CHEMBL1909164
(2)
|
0 / 0 |
| P29274 | Adenosine receptor A2a | Adenosine receptor | CHEMBL502620 |
CHEMBL1909214
(2)
|
0 / 0 |
| P25929 | Neuropeptide Y receptor type 1 | Neuropeptide Y receptor | CHEMBL502620 |
CHEMBL1909175
(2)
|
0 / 0 |
| P50052 | Type-2 angiotensin II receptor | Angiotensin receptor | CHEMBL502620 |
CHEMBL1909096
(2)
|
1 / 1 |
| P17948 | Vascular endothelial growth factor receptor 1 | Vegfr | CHEMBL502620 |
CHEMBL1909118
(2)
|
0 / 0 |
| P41968 | Melanocortin receptor 3 | Melanocortin receptor | CHEMBL502620 |
CHEMBL1909166
(2)
|
1 / 0 |
| P11509 | Cytochrome P450 2A6 | Cytochrome P450 2A6 | CHEMBL502620 |
CHEMBL1909133
(2)
|
0 / 0 |
| P04035 | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Oxidoreductase | CHEMBL502620 |
CHEMBL1909158
(2)
|
0 / 0 |
| P08913 | Alpha-2A adrenergic receptor | Adrenergic receptor | CHEMBL502620 |
CHEMBL1909088
(2)
|
0 / 0 |
| P21917 | D(4) dopamine receptor | Dopamine receptor | CHEMBL502620 |
CHEMBL1909142
(2)
|
0 / 0 |
| P30988 | Calcitonin receptor | Calcitonin receptor | CHEMBL502620 |
CHEMBL1909101
(2)
|
0 / 0 |
| P35462 | D(3) dopamine receptor | Dopamine receptor | CHEMBL502620 |
CHEMBL1909141
(2)
|
1 / 0 |
| P41143 | Delta-type opioid receptor | Opioid receptor | CHEMBL502620 |
CHEMBL1909180
(2)
|
0 / 0 |
| Q92731 | Estrogen receptor beta | NR3A2 | CHEMBL502620 |
CHEMBL1909146
(2)
|
0 / 1 |
| P41595 | 5-hydroxytryptamine receptor 2B | Serotonin receptor | CHEMBL502620 |
CHEMBL1909104
(2)
|
0 / 0 |
| P25101 | Endothelin-1 receptor | Endothelin receptor | CHEMBL502620 |
CHEMBL1909144
(2)
|
0 / 0 |
| P30411 | B2 bradykinin receptor | Bradykinin receptor | CHEMBL502620 |
CHEMBL1909100
(2)
|
0 / 0 |
| P32245 | Melanocortin receptor 4 | Melanocortin receptor | CHEMBL502620 |
CHEMBL1909167
(2)
|
1 / 0 |
| P32238 | Cholecystokinin receptor type A | Cholecystokinin receptor | CHEMBL502620 |
CHEMBL1909129
(2)
|
0 / 0 |
| P08311 | Cathepsin G | S1A | CHEMBL502620 |
CHEMBL1909194
(2)
|
0 / 0 |
| Q99720 | Sigma non-opioid intracellular receptor 1 | Membrane receptor | CHEMBL502620 |
CHEMBL1909110
(2)
|
1 / 0 |
| P03956 | Interstitial collagenase | M10A | CHEMBL502620 |
CHEMBL1909196
(2)
|
0 / 1 |
| P32241 | Vasoactive intestinal polypeptide receptor 1 | Vasoactive intestinal peptide receptor | CHEMBL502620 |
CHEMBL1909119
(2)
|
0 / 0 |
| P04150 | Glucocorticoid receptor | NR3C1 | CHEMBL502620 |
CHEMBL1909150
(2)
|
0 / 1 |
| P08172 | Muscarinic acetylcholine receptor M2 | Acetylcholine receptor | CHEMBL502620 |
CHEMBL1909171
(2)
|
2 / 0 |
| P11229 | Muscarinic acetylcholine receptor M1 | Acetylcholine receptor | CHEMBL502620 |
CHEMBL1909170
(2)
|
0 / 0 |
| P21554 | Cannabinoid receptor 1 | Cannabinoid receptor | CHEMBL502620 |
CHEMBL1909122
(2)
|
0 / 0 |
| P31645 | Sodium-dependent serotonin transporter | Serotonin | CHEMBL502620 |
CHEMBL1909109
(2)
|
2 / 0 |
| P04626 | Receptor tyrosine-protein kinase erbB-2 | TK tyrosine-protein kinase EGFR subfamily | CHEMBL502620 |
CHEMBL1909205
(2)
|
5 / 10 |
| P20309 | Muscarinic acetylcholine receptor M3 | Acetylcholine receptor | CHEMBL502620 |
CHEMBL1909172
(2)
|
1 / 0 |
| P21452 | Substance-K receptor | Neurokinin receptor | CHEMBL502620 |
CHEMBL1909114
(2)
|
0 / 0 |
| P51679 | C-C chemokine receptor type 4 | CC chemokine receptor | CHEMBL502620 |
CHEMBL1909125
(2)
|
0 / 0 |
| P51681 | C-C chemokine receptor type 5 | CC chemokine receptor | CHEMBL502620 |
CHEMBL1909126
(2)
|
3 / 0 |
| P50406 | 5-hydroxytryptamine receptor 6 | Serotonin receptor | CHEMBL502620 |
CHEMBL1909108
(2)
|
0 / 0 |
| P41597 | C-C chemokine receptor type 2 | CC chemokine receptor | CHEMBL502620 |
CHEMBL1909124
(2)
|
1 / 0 |
| P28482 | Mitogen-activated protein kinase 1 | Erk | CHEMBL502620 |
CHEMBL1909200
(2)
|
0 / 0 |
| P08575 | Receptor-type tyrosine-protein phosphatase C | Enzyme | CHEMBL502620 |
CHEMBL1909207
(2)
|
2 / 1 |
| P05177 | Cytochrome P450 1A2 | Cytochrome P450 1A2 | CHEMBL502620 |
CHEMBL1909132
(2)
|
0 / 0 |
| P08253 | 72 kDa type IV collagenase | M10A | CHEMBL502620 |
CHEMBL662787
(1)
|
1 / 3 |
| O76074 | cGMP-specific 3',5'-cyclic phosphodiesterase | PDE_5A | CHEMBL502620 |
CHEMBL1909186
(2)
|
0 / 0 |
| P03372 | Estrogen receptor | NR3A1 | CHEMBL502620 |
CHEMBL1909145
(2)
|
1 / 1 |
| P08588 | Beta-1 adrenergic receptor | Adrenergic receptor | CHEMBL502620 |
CHEMBL1909091
(2)
|
1 / 0 |
| P22303 | Acetylcholinesterase | Hydrolase | CHEMBL502620 |
CHEMBL1909212
(2)
|
1 / 0 |
| P28223 | 5-hydroxytryptamine receptor 2A | Serotonin receptor | CHEMBL502620 |
CHEMBL1909211
(2)
|
0 / 0 |
| P28335 | 5-hydroxytryptamine receptor 2C | Serotonin receptor | CHEMBL502620 |
CHEMBL1909105
(2)
|
0 / 0 |
| P35372 | Mu-type opioid receptor | Opioid receptor | CHEMBL502620 |
CHEMBL1909182
(2)
|
0 / 0 |
| P08173 | Muscarinic acetylcholine receptor M4 | Acetylcholine receptor | CHEMBL502620 |
CHEMBL1909173
(2)
|
0 / 0 |
| P25103 | Substance-P receptor | Neurokinin receptor | CHEMBL502620 |
CHEMBL1909113
(2)
|
0 / 0 |
| P25105 | Platelet-activating factor receptor | PAF receptor | CHEMBL502620 |
CHEMBL1909187
(2)
|
0 / 0 |
| P33032 | Melanocortin receptor 5 | Melanocortin receptor | CHEMBL502620 |
CHEMBL1909168
(2)
|
0 / 0 |
| P33261 | Cytochrome P450 2C19 | Cytochrome P450 2C19 | CHEMBL502620 |
CHEMBL1909134
(2)
|
1 / 1 |
| P08684 | Cytochrome P450 3A4 | Cytochrome P450 3A4 | CHEMBL502620 |
CHEMBL1909138
(2)
|
0 / 1 |
| P05181 | Cytochrome P450 2E1 | Cytochrome P450 2E1 | CHEMBL502620 |
CHEMBL1909137
(2)
|
0 / 0 |
| P07477 | Trypsin-1 | S1A | CHEMBL502620 |
CHEMBL813733
(1)
|
1 / 1 |
| P23975 | Sodium-dependent noradrenaline transporter | Norepinephrine | CHEMBL502620 |
CHEMBL1909094
(2)
|
1 / 1 |
| P25100 | Alpha-1D adrenergic receptor | Adrenergic receptor | CHEMBL502620 |
CHEMBL1909087
(2)
|
0 / 0 |
| P30542 | Adenosine receptor A1 | Adenosine receptor | CHEMBL502620 |
CHEMBL1909213
(2)
|
0 / 0 |
| P18089 | Alpha-2B adrenergic receptor | Adrenergic receptor | CHEMBL502620 |
CHEMBL1909089
(2)
|
0 / 0 |
| P24557 | Thromboxane-A synthase | Cytochrome P450 5A1 | CHEMBL502620 |
CHEMBL1909116
(2)
|
1 / 1 |
| P06239 | Tyrosine-protein kinase Lck | Src | CHEMBL502620 |
CHEMBL1909206
(2)
|
0 / 1 |
| P25025 | C-X-C chemokine receptor type 2 | CXC chemokine receptor | CHEMBL502620 |
CHEMBL1909128
(2)
|
0 / 0 |
CTD interaction (23)
| compound | gene | gene name | gene description | interaction | interaction type | form |
reference
pmid |
|---|---|---|---|---|---|---|---|
| D015250 | 836 |
CASP3
CPP32 CPP32B SCA-1 |
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) | Aclarubicin results in increased activity of CASP3 protein |
increases activity
|
protein |
20399885
|
| D015250 | 841 |
CASP8
ALPS2B CAP4 Casp-8 FLICE MACH MCH5 |
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) | Aclarubicin results in increased activity of CASP8 protein |
increases activity
|
protein |
20399885
|
| D015250 | 1676 |
DFFA
DFF-45 DFF1 ICAD |
DNA fragmentation factor, 45kDa, alpha polypeptide | Aclarubicin results in increased degradation of DFFA protein |
increases degradation
|
protein |
12370496
|
| D015250 | 2623 |
GATA1
ERYF1 GATA-1 GF-1 GF1 NF-E1 NFE1 XLANP XLTDA XLTT |
GATA binding protein 1 (globin transcription factor 1) | Acetylcysteine inhibits the reaction [Aclarubicin results in increased expression of GATA1 mRNA] |
decreases reaction
/ increases expression |
mRNA |
10656287
|
| D015250 | 2623 |
GATA1
ERYF1 GATA-1 GF-1 GF1 NF-E1 NFE1 XLANP XLTDA XLTT |
GATA binding protein 1 (globin transcription factor 1) | Aclarubicin promotes the reaction [GATA1 protein binds to GSTP1 promoter] |
affects binding
/ increases reaction |
protein |
14623254
|
| D015250 | 2623 |
GATA1
ERYF1 GATA-1 GF-1 GF1 NF-E1 NFE1 XLANP XLTDA XLTT |
GATA binding protein 1 (globin transcription factor 1) | Aclarubicin results in increased activity of GATA1 protein |
increases activity
|
protein |
14623254
|
| D015250 | 2623 |
GATA1
ERYF1 GATA-1 GF-1 GF1 NF-E1 NFE1 XLANP XLTDA XLTT |
GATA binding protein 1 (globin transcription factor 1) | Aclarubicin results in increased expression of GATA1 mRNA |
increases expression
|
mRNA |
10656287
|
| D015250 | 2623 |
GATA1
ERYF1 GATA-1 GF-1 GF1 NF-E1 NFE1 XLANP XLTDA XLTT |
GATA binding protein 1 (globin transcription factor 1) | pyrrolidine dithiocarbamic acid inhibits the reaction [Aclarubicin results in increased expression of GATA1 mRNA] |
decreases reaction
/ increases expression |
mRNA |
10656287
|
| D015250 | 2623 |
GATA1
ERYF1 GATA-1 GF-1 GF1 NF-E1 NFE1 XLANP XLTDA XLTT |
GATA binding protein 1 (globin transcription factor 1) | Quercetin inhibits the reaction [Aclarubicin results in increased expression of GATA1 mRNA] |
decreases reaction
/ increases expression |
mRNA |
10656287
|
| D015250 | 2950 |
GSTP1
DFN7 FAEES3 GST3 GSTP PI |
glutathione S-transferase pi 1 (EC:2.5.1.18) | Aclarubicin promotes the reaction [GATA1 protein binds to GSTP1 promoter] |
affects binding
/ increases reaction |
promoter |
14623254
|
| D015250 | 2950 |
GSTP1
DFN7 FAEES3 GST3 GSTP PI |
glutathione S-transferase pi 1 (EC:2.5.1.18) | Aclarubicin results in increased expression of GSTP1 mRNA |
increases expression
|
mRNA |
14623254
|
| D015250 | 2950 |
GSTP1
DFN7 FAEES3 GST3 GSTP PI |
glutathione S-transferase pi 1 (EC:2.5.1.18) | Aclarubicin results in increased expression of GSTP1 protein |
increases expression
|
protein |
14623254
|
| D015250 | 3145 |
HMBS
PBG-D PBGD PORC UPS |
hydroxymethylbilane synthase (EC:2.5.1.61) | Acetylcysteine inhibits the reaction [Aclarubicin results in increased expression of HMBS mRNA] |
decreases reaction
/ increases expression |
mRNA |
10656287
|
| D015250 | 3145 |
HMBS
PBG-D PBGD PORC UPS |
hydroxymethylbilane synthase (EC:2.5.1.61) | Aclarubicin results in increased expression of HMBS mRNA |
increases expression
|
mRNA |
10656287
|
| D015250 | 3145 |
HMBS
PBG-D PBGD PORC UPS |
hydroxymethylbilane synthase (EC:2.5.1.61) | pyrrolidine dithiocarbamic acid inhibits the reaction [Aclarubicin results in increased expression of HMBS mRNA] |
decreases reaction
/ increases expression |
mRNA |
10656287
|
| D015250 | 3145 |
HMBS
PBG-D PBGD PORC UPS |
hydroxymethylbilane synthase (EC:2.5.1.61) | Quercetin inhibits the reaction [Aclarubicin results in increased expression of HMBS mRNA] |
decreases reaction
/ increases expression |
mRNA |
10656287
|
| D015250 | 4778 |
NFE2
NF-E2 p45 |
nuclear factor, erythroid 2 | Acetylcysteine inhibits the reaction [Aclarubicin results in increased expression of NFE2 mRNA] |
decreases reaction
/ increases expression |
mRNA |
10656287
|
| D015250 | 4778 |
NFE2
NF-E2 p45 |
nuclear factor, erythroid 2 | Aclarubicin results in increased expression of NFE2 mRNA |
increases expression
|
mRNA |
10656287
|
| D015250 | 4778 |
NFE2
NF-E2 p45 |
nuclear factor, erythroid 2 | pyrrolidine dithiocarbamic acid inhibits the reaction [Aclarubicin results in increased expression of NFE2 mRNA] |
decreases reaction
/ increases expression |
mRNA |
10656287
|
| D015250 | 4778 |
NFE2
NF-E2 p45 |
nuclear factor, erythroid 2 | Quercetin inhibits the reaction [Aclarubicin results in increased expression of NFE2 mRNA] |
decreases reaction
/ increases expression |
mRNA |
10656287
|
| D015250 | 142 |
PARP1
ADPRT ADPRT_1 ADPRT1 ARTD1 PARP PARP-1 PPOL pADPRT-1 |
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) | Aclarubicin affects the activity of PARP1 protein |
affects activity
|
protein |
20399885
|
| D015250 | 6647 |
SOD1
ALS ALS1 IPOA SOD hSod1 homodimer |
superoxide dismutase 1, soluble (EC:1.15.1.1) | Aclarubicin results in decreased activity of SOD1 protein |
decreases activity
|
protein |
10656287
|
| D015250 | 331 |
XIAP
API3 BIRC4 IAP-3 ILP1 MIHA XLP2 hIAP-3 hIAP3 |
X-linked inhibitor of apoptosis | XIAP protein results in increased susceptibility to Aclarubicin |
increases response to substance
|
protein |
10815900
|
Related Disease
Diseases related to proteins in ChEMBL interactions
OMIM (38)
| OMIM | preferred title | UniProt |
|---|---|---|
| #100100 | Abdominal muscles, absence of, with urinary tract abnormality and cryptorchidism |
P20309
|
| #103780 | Alcohol dependence |
P08172
P14416 P31645 |
| #614373 | Amyotrophic lateral sclerosis 16, juvenile; als16 |
Q99720
|
| #602025 | Body mass index quantitative trait locus 9; bmiq9 |
P41968
|
| #300615 | Brunner syndrome |
P21397
|
| #162800 | Cyclic neutropenia |
P08246
|
| #612522 | Diabetes mellitus, insulin-dependent, 22; iddm22 |
P51681
|
| #609535 | Drug metabolism, poor, cyp2c19-related |
P33261
|
| #608902 | Drug metabolism, poor, cyp2d6-related |
P10635
|
| #615363 | Estrogen resistance; estrr |
P03372
|
| #613659 | Gastric cancer |
P04626
|
| #137215 | Gastric cancer, hereditary diffuse; hdgc |
P04626
|
| #231095 | Ghosal hematodiaphyseal dysplasia; ghdd |
P24557
|
| #137800 | Glioma susceptibility 1; glm1 |
P04626
|
| #609423 | Human immunodeficiency virus type 1, susceptibility to |
P41597
P51681 |
| #603932 | Intervertebral disc disease; idd |
P14780
|
| #613688 | Long qt syndrome 2; lqt2 |
Q12809
|
| #211980 | Lung cancer |
P00533
P04626 |
| #608516 | Major depressive disorder; mdd |
P08172
|
| %300852 | Mental retardation, x-linked 88; mrx88 |
P50052
|
| #613073 | Metaphyseal anadysplasia 2; mandp2 |
P14780
|
| #259600 | Multicentric osteolysis, nodulosis, and arthropathy; mona |
P08253
|
| #126200 | Multiple sclerosis, susceptibility to; ms |
P08575
|
| #159900 | Myoclonic dystonia |
P14416
|
| #202700 | Neutropenia, severe congenital, 1, autosomal dominant; scn1 |
P08246
|
| #601665 | Obesity |
P32245
|
| #164230 | Obsessive-compulsive disorder; ocd |
P31645
|
| #604715 | Orthostatic intolerance |
P23975
|
| #259730 | Osteopetrosis, autosomal recessive 3; optb3 |
P00918
|
| #167000 | Ovarian cancer |
P04626
|
| #167800 | Pancreatitis, hereditary; pctt |
P07477
|
| #613135 | Parkinsonism-dystonia, infantile; pkdys |
Q01959
|
| #607276 | Resting heart rate, variation in |
P08588
|
| #608971 | Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive |
P08575
|
| #609620 | Short qt syndrome 1; sqt1 |
Q12809
|
| #190300 | Tremor, hereditary essential, 1; etm1 |
P35462
|
| #610379 | West nile virus, susceptibility to |
P51681
|
| #112100 | Yt blood group antigen |
P22303
|
KEGG DISEASE (33)
| KEGG | disease name | UniProt |
|---|---|---|
| H00016 | Oral cancer |
P00533
(related)
P00533 (marker) |
| H00017 | Esophageal cancer |
P00533
(related)
P35354 (related) |
| H00018 | Gastric cancer |
P00533
(related)
P04626 (related) |
| H00022 | Bladder cancer |
P00533
(related)
P04626 (related) |
| H00028 | Choriocarcinoma |
P00533
(related)
P03956 (related) P04626 (related) P08253 (related) |
| H00030 | Cervical cancer |
P00533
(related)
P04626 (related) |
| H00042 | Glioma |
P00533
(related)
P00533 (marker) |
| H00055 | Laryngeal cancer |
P00533
(related)
P00533 (marker) |
| H00241 | Combined proximal and distal renal tubular acidosis (RTA type 3) |
P00918
(related)
|
| H00436 | Osteopetrosis |
P00918
(related)
|
| H00026 | Endometrial Cancer |
P03372
(marker)
P04626 (related) Q92731 (marker) |
| H00599 | 46,XX disorders of sex development (Disorders related to androgen excess) |
P04150
(related)
|
| H00019 | Pancreatic cancer |
P04626
(related)
|
| H00027 | Ovarian cancer |
P04626
(related)
|
| H00031 | Breast cancer |
P04626
(related)
P04626 (marker) |
| H00046 | Cholangiocarcinoma |
P04626
(related)
P35354 (related) |
| H00093 | Combined immunodeficiencies (CIDs) |
P06239
(related)
|
| H00933 | Hereditary pancreatitis |
P07477
(related)
|
| H00079 | Asthma |
P07550
(related)
|
| H00100 | Neutropenic disorders |
P08246
(related)
|
| H00025 | Penile cancer |
P08253
(related)
P14780 (related) P35354 (related) |
| H00472 | Torg-Winchester syndrome |
P08253
(related)
|
| H00091 | T-B+Severe combined immunodeficiencies (SCIDs) |
P08575
(related)
|
| H00036 | Osteosarcoma |
P08684
(marker)
|
| H01205 | Coumarin resistance |
P11712
(related)
|
| H00479 | Metaphyseal dysplasias |
P14780
(related)
|
| H00548 | Brunner syndrome |
P21397
(related)
|
| H01031 | Orthostatic intolerance (OI) |
P23975
(related)
|
| H00490 | Diaphyseal dysplasia with anemia (Ghosal) |
P24557
(related)
|
| H01171 | Poor drug metabolism (PM) |
P33261
(related)
|
| H00480 | Non-syndromic X-linked mental retardation |
P50052
(related)
|
| H00720 | Long QT syndrome |
Q12809
(related)
|
| H00725 | Short QT syndrome |
Q12809
(related)
|